The story of Viagra presents a complex case for observers in the pharmaceutical sector. While initially a tremendous success, creating vast sums, the patent expiration and the subsequent flood of cheaper competitors have drastically impacted revenue. This poses questions about the ongoing profitability of related drug projects and suggests that jus